Thursday, February 23, 2017 10:36:50 AM
by Cynthia Koons
February 23, 2017, 5:00 AM EST
Jana adds board members to drugmaker, Icahn said to have stake
‘I think everybody is looking at Bristol,’ Allergan CEO says
Bristol-Myers Squibb Co. was once one of the drug industry’s highest-flying companies. Now the pharmaceutical giant has gone from predator to prey, as its sagging stock price has invited in activist investors who are already forcing changes.
On Tuesday, it announced an agreement with Jana Partners LLC to add three board members, and later in the day activist investor Carl Icahn was reported to have taken a stake and sees the drugmaker as potentially ripe for a takeover. Potential buyers could include Pfizer Inc., Gilead Sciences Inc. and Novartis AG, all of which have an interest in cancer and have money to spend.
“I think everybody is looking at Bristol,” Allergan Plc CEO Brent Saunders said in an interview at Bloomberg headquarters in New York on Wednesday. Saunders said it would be a “very, very high hurdle” for a company like Allergan to do such a deal, but for any CEO, “you’re going to at least take five minutes to think about it.”
Bristol-Myers was itself once one of the drug industry’s major acquirers, snapping up pipeline assets in what it referred to as its “string of pearls” strategy. Those deals landed it the drug Opdivo, which used the immune system to attack cancers and got remarkable results in once-fatal diseases like advanced melanoma. More recently, though, it’s lost ground to rivals like Merck & Co., which has a similar drug, Keytruda, that has taken the lead in some oncology markets.
Tempting Target
Bristol-Myers is still a tempting target. “If you believe in the immuno-oncology franchise, then it’s obviously an attractive asset because there’s not many ways to get into this space,” said David Heupel, a senior health-care analyst at Thrivent Financial.
A takeover of Bristol-Myers would be one of the industry’s largest ever. It commands a market valuation of about $92.6 billion, compared with almost $130 billion in July. That’s big, but not too big for some of the drug giants.
While Pfizer has a partnership with Germany’s Merck KGaA in immune-system-based cancer drugs, it’s well behind Bristol-Myers and Merck. Novartis, another player in oncology, could raise the cash to do a deal through asset sales and debt. Gilead has amassed billions of dollars from sales of its hepatitis C drugs and is looking for its next move.
Spokesmen for Pfizer, Bristol-Myers and Gilead all declined to comment.
A Pfizer deal for Bristol-Myers would make sense “if they feel like they needed to make a move and become a very relevant player in immuno-oncology,” said Thrivent’s Heupel. His fund owns shares of both.
Potential Buyers
Novartis, meanwhile, may have money to spend. The Swiss drugmaker said last month it’s weighing options including a spinoff or IPO for its Alcon eye-care unit, which could generate as much as $20 billion, according to Bloomberg Intelligence. It also has a stake in Roche AG that could be worth another $13 billion, and could raise the rest via debt and by offering stock in a deal.
Gilead needs to make up for its fading blockbuster hepatitis C franchise, which brought in $14.8 billion last year but is capturing fewer patients. Chief Executive Officer John Milligan has said he’s anxious to do deals in areas including cancer. In January, Gilead hired Novartis’ former head of global oncology development, Alessandro Riva, to oversee its efforts in oncology and hematology.
The company has a “nascent oncology platform, but what I don’t yet see is a drug that we can rally around,” Milligan said in a May interview.
Carl Icahn
Icahn’s stake in Bristol-Myers was reported by the Wall Street Journal on Tuesday, and he sees the drugmaker as a potential acquisition target, the Journal said, citing people familiar with the matter. The investor has a history of taking positions in companies and then working to force a sale. Worth about $20 billion, according to the Bloomberg Billionaires Index, Icahn primarily invests his own fortune. He endorsed Saunders becoming CEO of Forest Laboratories Inc., one of his first CEO jobs, after taking a position in Forest.
“Carl is a very smart, thoughtful investor. I have to believe that he looks at Bristol-Myers and the industry and he’s saying, ‘Great company, great pipeline and an industry that should potentially consolidate.’ So that’s a formula that Carl tends to like,” Saunders said. Spokesmen for Icahn didn’t respond to requests for comment.
Another factor that could accelerate pharma merger and acquisition activity is U.S. tax reform. U.S. drugmakers have tens of billions of dollars in profits held overseas in lower-tax jurisdictions, and there has been discussion about a tax holiday to let the money come back at a lower rate. While tax reform won’t drive the company’s strategy, Pfizer CEO Ian Read said on a call last month with analysts, it could help.
“Some deals that previously would not have been affordable may now be affordable,” Read said.
_____________________________________________
https://www.bloomberg.com/news/articles/2017-02-23/bristol-myers-looms-as-pharma-s-next-megadeal-as-activists-join
BMY
Recent BMY News
- Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases • PR Newswire (US) • 04/29/2024 10:00:00 AM
- CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma • Business Wire • 04/26/2024 10:59:00 AM
- U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast • IH Market News • 04/25/2024 11:53:54 AM
- Bristol Myers Squibb Reports First Quarter Financial Results for 2024 • Business Wire • 04/25/2024 10:59:00 AM
- Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News • IH Market News • 04/23/2024 11:25:34 AM
- Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster • Business Wire • 04/22/2024 10:59:00 AM
- Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster • Business Wire • 04/22/2024 10:59:00 AM
- KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) • Business Wire • 04/08/2024 03:30:00 PM
- Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society • Business Wire • 04/06/2024 05:15:00 PM
- Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society • Business Wire • 04/06/2024 05:15:00 PM
- U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy • Business Wire • 04/05/2024 01:05:00 PM
- European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) • Business Wire • 04/03/2024 12:08:00 AM
- Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals • Business Wire • 04/02/2024 10:59:00 AM
- Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung… • Business Wire • 03/28/2024 08:05:00 PM
- Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease • Business Wire • 03/28/2024 08:01:00 PM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 11:30:08 AM
- A Bristol Myers Squibb Expande as Iniciativas de Doações para a Equidade em Saúde a fim de Melhorar os Resultados de Saúde • Business Wire • 03/26/2024 06:25:00 PM
- Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes • Business Wire • 03/26/2024 10:59:00 AM
- Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio • Business Wire • 03/25/2024 12:00:00 PM
- Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma • Business Wire • 03/20/2024 08:45:00 PM
- Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma • Business Wire • 03/20/2024 10:59:00 AM
- Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign • Business Wire • 03/19/2024 10:59:00 AM
- Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio • Business Wire • 03/18/2024 12:44:00 PM
- FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy • Business Wire • 03/15/2024 10:27:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM